Cargando…
When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine
Autores principales: | Dal-Ré, Rafael, Banzi, Rita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973077/ https://www.ncbi.nlm.nih.gov/pubmed/33810939 http://dx.doi.org/10.1016/j.ejim.2021.03.016 |
Ejemplares similares
-
Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label
por: Dal-Ré, Rafael, et al.
Publicado: (2021) -
The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans
por: Dal-Ré, Rafael
Publicado: (2023) -
AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021) -
Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021) -
Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021)